Search PubMed⌕ Search

PubMed · 16022146

Liquid ventilation.

Abstract

Respiratory diseases are the commonest cause of morbidity and mortality in newborn babies. During the past few years several new modalities of treatment like surfactant have been introduced. One of them, and probably the most fascinating, is of liquid ventilation. Partial liquid ventilation, on which much of the existing research has concentrated, requires partial filling of lungs with perfluorocarbons (PFC's) and ventilation with gas tidal volumes using a conventional mechanical ventilators. Various physico-chemical properties of PFC's make them the ideal media. It results in a dramatic improvement in lung compliance and oxygenation and decline in mean airway pressure and oxygen requirements. It shows further promise for lung lavaging procedures, pulmonary image enhancement, pulmonary administration of drugs and as a technique to increase functional residual capacity in lung hypoplasia syndromes. There are no long-term side effect reported.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Arvind Sehgal, Robert Guaran. Liquid ventilation.. https://pubmed.ncbi.nlm.nih.gov/16022146/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Investigating the degradation potential of microbial consortia for perfluorooctane sulfonate through a functional "top-down" screening approach.

Perfluorooctane sulfonate (PFOS) is a prominent perfluorinated compound commonly found in the environment, known to pose various risks to human health. However, the removal of PFOS presents significant challenges, primarily due to the limited discovery of bacteria capable of effectively degrading PFOS. Moreover, single degradation bacteria often encounter obstacles in individual cultivation and the breakdown of complex pollutants. In contrast, microbial consortia have shown promise in pollutant degradation. This study employed a continuous enrichment method, combined with multiple co-metabolic substrates, to investigate a microbial consortium with the potential for PFOS degradation. By employing this methodology, we effectively identified a microbial consortium that demonstrated the capacity to reduce PFOS when exposed to an optimal concentration of methanol. The consortium predominantly comprised of Hyphomicrobium species (46.7%) along with unclassified microorganisms (53.0%). Over a duration of 20 days, the PFOS concentration exhibited a notable decrease of 56.7% in comparison to the initial level, while considering the exclusion of adsorption effects. Furthermore, by comparing the predicted metabolic pathways of the microbial consortium with the genome of a known chloromethane-degrading bacterium, Hyphomicrobium sp. MC1, using the KEGG database, we observed distinct variations in the metabolic pathways, suggesting the potential role of the unclassified microorganisms. These findings underscore the potential effectiveness of a "top-down" functional microbial screening approach in the degradation of stubborn pollutants.

Fluorocarbons↗

Anterior ischemic optic neuropathy after uncomplicated scleral buckling surgery.

BACKGROUND: To report a case of non-arteritic anterior ischemic optic neuropathy (NAION) observed after uncomplicated scleral buckle placement. METHODS: A 57-year-old man presented with a rhegmatogenous retinal detachment of the left eye. He underwent uncomplicated scleral buckle placement and C3F8 injection. Perioperative intraocular pressures were normal. RESULTS: On postoperative day 24, fundus examination revealed swelling of the left optic nerve and features of an optic neuropathy (visual field defect, relative afferent pupillary defect). Fluorescein angiography did not reveal delayed choroidal filling. Review of systems and laboratory investigations were not consistent with giant cell arteritis. CONCLUSIONS: Non-arteritic anterior ischemic optic neuropathy may develop after uncomplicated scleral buckling surgery.

Fluorocarbons↗